A potent and selective pan-ALK inhibitor IC50=0.6 nM.1 Cells with ALK mutation L1196Q2 and the double mutation I1171S + G12693 remain sensitive to brigatinib. Clinically useful in non-small cell lung cancer.4
* VAT and and shipping costs not included. Errors and price changes excepted